Cullen Frost Bankers Inc. Buys 12,516 Shares of Kenvue Inc. (NYSE:KVUE)

Cullen Frost Bankers Inc. grew its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 3.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 347,789 shares of the company's stock after buying an additional 12,516 shares during the period. Cullen Frost Bankers Inc.'s holdings in Kenvue were worth $8,340,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Fulton Bank N.A. lifted its stake in shares of Kenvue by 0.6% in the 1st quarter. Fulton Bank N.A. now owns 78,888 shares of the company's stock valued at $1,892,000 after purchasing an additional 465 shares during the last quarter. Scott & Selber Inc. increased its stake in Kenvue by 0.4% in the first quarter. Scott & Selber Inc. now owns 106,621 shares of the company's stock valued at $2,557,000 after acquiring an additional 475 shares during the period. Keystone Financial Group increased its stake in Kenvue by 4.8% in the fourth quarter. Keystone Financial Group now owns 12,736 shares of the company's stock valued at $272,000 after acquiring an additional 578 shares during the period. Transatlantique Private Wealth LLC boosted its position in Kenvue by 5.7% in the fourth quarter. Transatlantique Private Wealth LLC now owns 10,680 shares of the company's stock valued at $228,000 after buying an additional 580 shares in the last quarter. Finally, Byrne Asset Management LLC boosted its position in Kenvue by 1.0% in the first quarter. Byrne Asset Management LLC now owns 63,467 shares of the company's stock valued at $1,522,000 after buying an additional 621 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

KVUE has been the subject of several recent analyst reports. Bank of America lowered their target price on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday. Citigroup reduced their target price on shares of Kenvue from $24.50 to $22.00 and set a "neutral" rating for the company in a report on Tuesday. Evercore ISI assumed coverage on shares of Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Redburn Atlantic assumed coverage on shares of Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target for the company. Finally, Barclays cut their price target on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $24.71.

Kenvue Stock Up 0.7%

Shares of KVUE stock traded up $0.15 during mid-day trading on Friday, reaching $22.00. 12,727,162 shares of the company's stock traded hands, compared to its average volume of 16,308,763. Kenvue Inc. has a 12 month low of $17.85 and a 12 month high of $25.17. The company has a market cap of $42.21 billion, a P/E ratio of 40.00, a P/E/G ratio of 3.41 and a beta of 0.83. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. The company's 50-day moving average price is $22.20 and its 200-day moving average price is $22.30.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same quarter in the previous year, the firm earned $0.28 EPS. Kenvue's quarterly revenue was down 3.9% compared to the same quarter last year. On average, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.